HLE Glascoat Ltd Q1 FY2026 Concall Summary

Key Takeaways

• Transformational asset acquisition at distressed value: HLE acquired OMERAS's assets for €2.75 mn, below inherent asset value, gaining a unique scaled player in architectural facades and glass-fused-to-steel tanks with no legacy liabilities.
• Clear, near-term turnaround path: OMERAS currently operates at ~50% capacity (~Rs. 200 cr revenue) with state-of-the-art equipment; management targets a healthy, profitable business within 3–4 quarters, with double-digit margins comparable to Thaletec.
• Organic business momentum intact: Consolidated organic growth guided at 16–18%, potentially closer to 20% based on the current order book, with the API segment delivering double-digit growth and peptide equipment orders already in hand.
• Acquisition is immediately and strongly EPS accretive: Financed entirely from internal accruals with no debt added, the deal is expected to be EPS accretive within 2–3 quarters and positive for ROE/ROCE.
• What to watch next quarter: The pace of OMERAS's operational turnaround and margin ramp, the conversion of the €28 mn order pipeline under negotiation, and any quantification of cross-selling traction with HLE's 1,500+ global customers.

The OMERAS Acquisition: What Was Bought and Why

• Asset deal, not a company purchase: HLE acquired specific assets of OMERAS GmbH: ~21,000 sqm of land and factory building (market value ~€1 mn), all equipment (value considerably higher), intangibles including the OMERAS brand and technical know-how, and all inventory as of the transfer date. No liabilities were acquired, and no EPC orders that caused past losses were taken over.
• Two distinct, scaled businesses under one roof: OMERAS operates in architectural facades (vitreous enamel coating, advanced metal processing) and, through OMERAS Store, glass-fused-to-steel tanks and silos from 8 to over 20,000 cubic meters for water, wastewater, biogas, and grain storage.
• Unique competitive moat: OMERAS is the only player globally that masters both tanks/silos and architectural facades at scale. In the architectural business, management stated no other company can deliver at the scale OMERAS can, a structural advantage that HLE now owns.
• Acquired below asset value: The €2.75 mn purchase price is less than the inherent asset value of the land, building, and equipment alone, meaning HLE paid nothing for the business or brand. The entire transaction was funded from internal accruals with no incremental debt.
• Clean employee transition: All existing employees are being issued fresh appointment letters; all legacy pension obligations have been fully paid out and funded, with zero carry-forward pension liabilities. Future pension costs will flow through the P&L as a fresh cost for services rendered.

Patel: "OMERAS is the only one who actually masters both. So there are very few players who are actually able to deliver quality products in both these spaces."

Turnaround Economics and Timeline

• Low utilization, high operating leverage: OMERAS currently runs at ~50% capacity utilization, generating roughly Rs. 200 crores in revenue. Full capacity would approximately double that, with no major CAPEX required since equipment is state-of-the-art and largely new, featuring laser cutting lines and automation in metalworking and glass lining.
• Profitability target within 3–4 quarters: Management expects OMERAS to become a healthy, profitable business within that window, targeting double-digit operating and net profit margins comparable to Thaletec, HLE's prior successful European acquisition.
• Historical performance supports the thesis: Before pandemic disruptions, surging European energy costs, and EPC project delays compressed EBITDA to 4% and pushed PAT negative, OMERAS had demonstrated steady revenue growth and resilient gross margins (54.3% in 2024). HLE is acquiring the core manufacturing capability without the loss-making EPC contracts.
• Revenue visibility building: OMERAS carries a €7 mn order book, with an additional €28 mn under negotiation. Once finalized, those orders will execute over 12–18 months. Biogas opportunities are under separate discussion and not yet included in either figure.
• FY27 as the true indicator: OMERAS will be consolidated for only ~7 months in the current fiscal year. Management cautioned that the next 1–2 quarters will not reflect the acquisition's full potential; FY27, with expected revenue of €20–€25 mn, will be the proper benchmark.

Ganjwala: "We are acquiring OMERAS at a value which is less than its inherent asset value. So we are not even talking of business valuations here."

Organic Business and Consolidated Growth Outlook

• Consolidated organic growth in high teens: Management guided 16–18% annual growth on a consolidated basis, with potential to approach 20% given the current order book. The OMERAS contribution will be additive on top of that base.
• API and pharma momentum strong: The API portion of the pharmaceutical business delivered double-digit growth year-on-year, with investments flowing into the pharmaceutical industry across Europe and the US. Peptide equipment orders have already been received and are in the process of being supplied.
• Margin profile seasonally back-half weighted: Historically, the first 1–2 quarters are softer than the latter half of the year. Volumes grew substantially in the Filtration & Drying and European Glass Lined equipment businesses during Q1, and the Indian Glass Lined segment is seeing good order inflow that will reflect in revenues and margins going forward.
• Consolidated margin ambition: All businesses have potential to reach mid-to-high teens operating margins, with Kinam exceeding 20%. On a blended basis, management is aiming for mid-to-high teens consolidated margins.
• Kinam amalgamation near completion: The NCLT final hearing was held and the scheme approved in open court, with the written order expected within days. Kinam operates in customized heat transfer solutions, differentiated from traditional fabricators, and can execute close to 3,000 heat exchangers annually while meeting global standards including PED, U-stamp, EAC, GIS, and CELO.

Strategic Rationale and Cross-Selling Potential

• Portfolio diversification beyond pharma and chemicals: OMERAS adds large storage tanks, silos, biogas digestion tanks, and architectural panels, reducing HLE's dependence on traditional chemical and API industry clientele.
• European base opens new geographies: The OMERAS facility provides a European manufacturing foothold, opening doors in Europe and the Middle East while positioning HLE for tender-based projects in Asia Pacific, Africa, and Latin America. Management also intends to address the US market for grain storage facilities in due course.
• Cross-selling into a 1,500+ customer network: Combining OMERAS's installed base and credibility with HLE's global customer network creates a direct cross-selling channel that management expects to unlock strong synergies.
• Secular tailwinds in water, biogas, and infrastructure: The European Green Deal and energy transition agenda are driving investments in renewable energy and biogas projects. Global water and wastewater infrastructure investments are projected to exceed US \$100 bn annually by 2030. HLE has clear plans to manufacture and market these products in India, particularly for biogas and infrastructure projects like Metro Rail and tunnels.
• Disciplined, value-driven acquisition philosophy: Management emphasized they are not shopping for acquisitions or pursuing growth for its own sake. They act only when they find value and synergies in a target, as they did with OMERAS.

Ganjwala: "I do not entirely agree or we do not entirely agree that the industry or the industrial scenario in Europe, in general, is bleak. I think there are certain pockets and there will always be certain industries which may not do well. But in general, for example, our experience with the Thaletec acquisition has been very good."

Financial Impact: Accretion, Margins, and Balance Sheet

• Immediate EPS accretion: The deal is expected to be EPS accretive within 2 quarters, with a worst-case scenario of 3 quarters, driven by the below-asset-value purchase price and the absence of incremental debt.
• ROE/ROCE tailwind: Because the acquisition was made below book value, the impact on return ratios is expected to be extremely positive from the outset.
• OMERAS margin trajectory: EBITDA margins for OMERAS are expected to reach double-digit mid-teens over the next 1–2 years, broadly in line with the overall profitability profile of HLE's European business.
• Debt strategy unchanged: The broad direction on debt reduction remains intact, with management committed to keeping debt within very reasonable levels. The OMERAS acquisition, being internally funded, does not alter that trajectory.
• No near-term CAPEX burden: Given low capacity utilization, no CAPEX is required from a capacity standpoint. Only incremental balancing equipment may be added, with land available for future expansion if needed.

Ganjwala: "The deal will be EPS accretive in hopefully 2 quarters, worst-case scenario, 3 quarters."

Guidance & Commitments

Key Metrics